Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Correlation between response and survival].

A Ohtsu1, N Boku, Y Miyata

  • 1Division of GI Oncology/Digestive Endoscopy, National Cancer Center Hospital East, Kashiwa, Japan.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|June 1, 2000
PubMed
Summary

Cancer chemotherapy endpoints focus on survival and quality of life, not just response rates. Phase III trials require survival data, not just phase II response rates, for robust evidence.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cancer registry as external control data for regulatory submission in Japan.

ESMO real world data and digital oncology·2026
Same author

Prognostic factors for overall survival in advanced digestive neuroendocrine carcinoma treated with first-line cisplatin-based chemotherapy: a <i>post hoc</i> analysis of JCOG1213.

ESMO gastrointestinal oncology·2026
Same author

The emerging role of real-world data in oncology care in Japan.

ESMO real world data and digital oncology·2026
Same author

ARCAD-Asia initiative: leveraging yesterday's data for tomorrow.

ESMO gastrointestinal oncology·2026
Same author

WJOG18524G: a single-arm phase II study evaluating bemarituzumab combined with ramucirumab and paclitaxel in fibroblast growth factor receptor 2b (FGFR2b)-positive advanced gastric or gastroesophageal junction cancer (RAINBIRD).

ESMO gastrointestinal oncology·2026
Same author

A multicenter phase II study of eribulin for BRAF V600E mutant metastatic colorectal cancer: the BRAVERY study (EPOC1701).

ESMO open·2025

Area of Science:

  • Oncology
  • Clinical Trials
  • Cancer Chemotherapy

Context:

  • True cancer chemotherapy endpoints are survival, symptom palliation, and quality of life.
  • Response rate is a surrogate endpoint, often used in early-phase trials.
  • Recent advancements include new response criteria and objective survival markers.

Purpose:

  • To evaluate the correlation between response rates and survival prolongation in gastrointestinal malignancies.
  • To emphasize the importance of survival data over response rates in phase III trial design.
  • To highlight the need for high-quality, large-scale randomized phase III trials for definitive evidence.

Summary:

  • Chemotherapy for esophageal cancer showed a correlation between complete response (CR) and survival prolongation with chemoradiotherapy.

Related Experiment Videos

  • Gastric cancer patients receiving chemotherapy demonstrated a link between responders and prolonged survival.
  • Colorectal cancer chemotherapy data did not support a correlation between response and survival, despite literature suggestions.

    • Impact:

    • Findings underscore the need to consider survival data alongside response rates in phase II studies for phase III trial planning.
    • Establishes that robust "evidence" in cancer chemotherapy relies on large, high-quality randomized phase III trials.
    • Suggests that response rate alone is insufficient for definitive conclusions in cancer treatment efficacy.